DISCLAIMER: This link was displayed at 09:09:04 29/11/2021 and expires on 04/12/2021 if printed.

Go to http://testguide.adhb.govt.nz/EGuide/ for more information.

FLT3 Acquired Mutation Analysis
Also known as : [D835],[ITD]


DNA/RNA
Test performed by: LabPLUS - Dept. Diagnostic Genetics - Molecular Haematology


Specimen Collection

Note: All samples should be forwarded to LabPlus at room temperature within 24hours.


CPD4 mL CPD Blood (Preferred)
CPD4 mL CPD Bone Marrow (Preferred)
EDTA4 mL EDTA Blood
EDTA4 mL EDTA Bone Marrow
Turnaround Time: Within 2 weeks, 4 days
Diagnostic Use and Interpretation

This test looks for the FLT3 Internal Tandem Duplication (ITD) and D835 acquired mutations commonly seen in AML patients.  

FLT3 Allelic Ratio Analysis

NPM1 Mutation Analysis


Contact Information

To contact the Molecular Haematology team please call:

Auckland City Hospital   (09) 307 4949
Lablink   ext 22000
Prof. Peter Browett (Haematologist)     ext 9090-86281
Nikhil Ghallayan (Section Leader)   ext 22006
Molecular Haematology Lab   ext 22005

For more inforamtion about the Molecular Haematology service at LabPLUS:

Molecular Haematology information page




Information on FLT3 mutations:

FLT3 is a receptor tyrosine kinase which is preferentially expressed on the surface of acute myeloid leukaemia (AML) and B cell-lineage acute lymphoblastic leukaemia (ALL) cells.  Mutations in the FLT3 gene are the most frequent genetic alterations in AML patients. The majority of FLT3 mutations in AML are either internal tandem duplications (ITD) (15-35%) or a missense mutation of D835 within the activation loop (5-10%).  Both of these mutations can be identified by PCR using genomic DNA.  The ITD mutations can be identified directly on an agarose gel and the D835 mutations by Eco RV digestion of a PCR product.

References:
Kiyoi H and Naoe T. Methods in Mol Med (2006), 125, 189-197.
Kiyoi H and Naoe T. Int J Hematol (2006), 83, 301-308.


Last updated at 11:48:27 18/03/2021